
Alvogen appoints Faysal Kalmoua as EVP of portfolio
pharmafile | October 29, 2015 | Appointment | Medical Communications | Alvogen, Faysal Kalmoua
Alvogen has announced the appointment of Faysal Kalmoua as its new executive vice president of portfolio.
Kalmoua joins Alvogen with an impressive track record in the pharma industry. Originally a medicinal chemist, his many qualifications include a Masters in chemistry and a global executive MBA from Insead.
He began his career at Synthon, where he worked for more than 15 years, first as a project manager for some key products and subsequently as head of business development, project management and portfolio management. His main focus has been on ‘complex’ generics, including first-to-file/ first-to-market opportunities and paths to differentiate from competitors.
In his new role at Alvogen, Kalmoua will be responsible for leading the company’s portfolio, as Alvogen continues to expand its pipeline and show dynamic global growth.
“I have every confidence that Faysal’s invaluable experience in the pharmaceutical industry will be of great strategic value to the company,” Alvogen’s chief executive and chairman Robert Wessman comments. “His dynamic approach and impressive leadership skills make him the ideal man for this job and a true asset for our team.”
Faysal Kalmoua adds: “I am delighted to join a world class company like Alvogen, which has an impressive growth story and compelling strategy. I look forward to working closely with Alvogen’s employees and shareholders and support Alvogen on its growth journey to become a top ten global generics player.”
Related Content

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market
Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a …

Death row inmate whose execution was postponed found dead in cell
Scott Dozier, the death row inmate whose execution was stalled by court cases launched by …

Alvogen court case causes Nevada Judge to halt execution
A Nevada Judge has temporarily prevented the use of the sedative midazolam, in the execution …






